ECSP24035412A - Dendrones peptídicos y métodos de uso de los mismos - Google Patents

Dendrones peptídicos y métodos de uso de los mismos

Info

Publication number
ECSP24035412A
ECSP24035412A ECSENADI202435412A ECDI202435412A ECSP24035412A EC SP24035412 A ECSP24035412 A EC SP24035412A EC SENADI202435412 A ECSENADI202435412 A EC SENADI202435412A EC DI202435412 A ECDI202435412 A EC DI202435412A EC SP24035412 A ECSP24035412 A EC SP24035412A
Authority
EC
Ecuador
Prior art keywords
peptide
dendrones
methods
dendrons
therapy
Prior art date
Application number
ECSENADI202435412A
Other languages
English (en)
Inventor
Ronald James Christie
Morgan Audrey Urello
Hannah Vaughan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP24035412A publication Critical patent/ECSP24035412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La memoria descriptiva se refiere a dendrones peptídicos que comprenden uno o más residuos derivados de una lisina modificada de fórmula (I), a sistemas de administración farmacéutica que comprenden estos dendrones peptídicos, a composiciones farmacéuticas que los contienen, y a su uso en terapia.
ECSENADI202435412A 2021-10-08 2024-05-08 Dendrones peptídicos y métodos de uso de los mismos ECSP24035412A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163262269P 2021-10-08 2021-10-08

Publications (1)

Publication Number Publication Date
ECSP24035412A true ECSP24035412A (es) 2024-06-28

Family

ID=83995423

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202435412A ECSP24035412A (es) 2021-10-08 2024-05-08 Dendrones peptídicos y métodos de uso de los mismos

Country Status (19)

Country Link
US (1) US20240408220A1 (es)
EP (1) EP4412662A1 (es)
JP (1) JP2024537869A (es)
KR (1) KR20240082404A (es)
CN (1) CN118119411A (es)
AR (1) AR127281A1 (es)
AU (1) AU2022361764A1 (es)
CA (1) CA3233268A1 (es)
CL (1) CL2024001024A1 (es)
CO (1) CO2024005252A2 (es)
CR (1) CR20240185A (es)
DO (1) DOP2024000066A (es)
EC (1) ECSP24035412A (es)
IL (1) IL311853A (es)
MX (1) MX2024004334A (es)
PE (1) PE20241473A1 (es)
TW (1) TW202342497A (es)
UY (1) UY39976A (es)
WO (1) WO2023057975A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661289A1 (en) * 2006-08-17 2008-10-09 Zheng-Rong Lu Dendrimers and methods of making and using thereof
US9526693B2 (en) * 2010-03-16 2016-12-27 Sanford-Burnham Medical Research Inslilute Delivery of agents using interfering nanoparticles
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
US9745421B2 (en) * 2013-03-20 2017-08-29 The Regents Of The University Of California Dendronized polymers for nucleic acid delivery
US20220340899A1 (en) * 2019-08-07 2022-10-27 Universität Bern Stereoselective ph responsive peptide dendrimers for nucleic acid transfection
KR20230084520A (ko) * 2020-10-09 2023-06-13 스미토모 파마 가부시키가이샤 올리고 핵산 콘쥬게이트
WO2022212838A1 (en) * 2021-04-02 2022-10-06 Tiba Biotech Llc Dendritic architectures as nonviral vectors in gene delivery

Also Published As

Publication number Publication date
JP2024537869A (ja) 2024-10-16
CR20240185A (es) 2024-06-11
AU2022361764A1 (en) 2024-05-16
PE20241473A1 (es) 2024-07-17
US20240408220A1 (en) 2024-12-12
CL2024001024A1 (es) 2024-10-11
AR127281A1 (es) 2024-01-03
IL311853A (en) 2024-05-01
EP4412662A1 (en) 2024-08-14
CN118119411A (zh) 2024-05-31
TW202342497A (zh) 2023-11-01
UY39976A (es) 2023-04-14
CO2024005252A2 (es) 2024-05-10
MX2024004334A (es) 2024-04-24
CA3233268A1 (en) 2023-04-13
WO2023057975A1 (en) 2023-04-13
DOP2024000066A (es) 2024-05-31
KR20240082404A (ko) 2024-06-10

Similar Documents

Publication Publication Date Title
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR117652A1 (es) Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
CL2022001353A1 (es) Inhibidores de egfr
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
JOP20180026A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
ECSP22090761A (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
MX2024001396A (es) Conjugados anticuerpo-fármaco y métodos de uso de estos.
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CL2024001024A1 (es) Dendrones peptídicos y métodos de uso de los mismos
JOP20240074A1 (ar) تركيبات إنزالوتاميد سائلة فموية
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek
BR112023019917A2 (pt) Uso de uma composição farmacêutica
DOP2021000028A (es) Formulaciones de dendrímeros
AR129570A1 (es) Macrociclos que contienen indazol y su uso